Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19
The onset of the 2019 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic necessitated the identification of approved drugs to treat the disease, before the development, approval and widespread administration of suitable vaccines. To identify such a drug, we used a visual analytics...
Saved in:
Main Authors: | Daniel P. Smith (Author), Olly Oechsle (Author), Michael J. Rawling (Author), Ed Savory (Author), Alix M.B. Lacoste (Author), Peter John Richardson (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current Status of Baricitinib as a Repurposed Therapy for COVID-19
by: Maha Saber-Ayad, et al.
Published: (2021) -
Application of Baricitinib in Dermatology
by: Zhang J, et al.
Published: (2022) -
Remission of chronic actinic dermatitis on baricitinib: A case report
by: Jessica Maguire, et al.
Published: (2023) -
Successful treatment of cutaneous polyarteritis nodosa with baricitinib
by: Shihui Zhou, et al.
Published: (2024) -
The development of oral hairy leukoplakia during baricitinib therapy
by: Fahad Ahmed, BA, et al.
Published: (2024)